<DOC>
	<DOCNO>NCT00153933</DOCNO>
	<brief_summary>The purpose study evaluate side effect combination bortezomib Revlimid ( CC-5013 ) patient relapse relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Bortezomib Combination With CC-5013 Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>- Within 21 day start treatment follow test perform : physical exam ( include vital sign ) , ECG , neurological examination , blood test , urine test , bone marrow aspiration , x-rays MRI CT scan . - Patients receive bortezomib intravenously day 1,4,8 11 follow 10 day rest . CC-5013 give orally day 1-14 follow 7-dyas rest . One cycle last 21 day . This study evaluate different dose level bortezomib CC-5013 see dose level seem best people . There 8 dose level . - Patients assign dose level depend upon begin study dose level tolerate patient already study . Three six patient treat dose level observe one full cycle . Depending upon side effect , dose level increase , stay decreased one level next group . 10 additional patient treat dose thought best . - On day four treatment cycle blood test , vital sign review side effect perform . - On day eight treatment cycle blood test , vital sign , review side effect ECG perform prior medication administration . A bortezomib level take bortezomib infusion , 15 minute , 1/2 hour , 45 minute , 1 hour , 2 hour , 4 hour , 6 hour , 8 hour 12 hour dose . Additional blood level collect 24 , 48 , 72 hour dose . ( These blood level do first cycle ) . - On day 11 day 14 treatment cycle blood test , vital sign review side effect perform . - After 2 cycle treatment , doctor assess patient 's disease respond treatment . Additional test bone marrow biopsy , x-rays scan may perform . If disease stable get well , patient continue receive repeat cycle treatment . If disease get bad , dexamethasone may add treatment cycle . - If dexamethasone add , dose start day 1,2,4,5,8,9 11 21-day cycle . The disease reassess 2 additional cycle . If disease get bad , patient remove study . - Once 8 cycle treatment perform , disease fully assess blood test , bone marrow biopsy , x-rays scan . Again , determine disease stable get well , additional treatment cycle perform . If disease get bad , treatment stopped.. - A follow-up visit schedule one month last dose study drug include : physical exam , vital sign , neurological examination , review symptom . - Patients remain study long side effect severe disease progress .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Diagnosis multiple myeloma base standard diagnosis criterion : plasmacytoma tissue biopsy ; bone marrow plasmacytosis ; monoclonal immunoglobulin spike serum electrophoresis ; lytic bone lesion . Must relapse relapsed/refractory disease 18 year age old All baseline study must perform within 21 day enrollment . ECOG performance status 0 2 Renal insufficiency ( serum creatinine level &gt; 2mg/dL ) Concomitant therapy medication include corticosteroid Peripheral neuropathy Grade 3 great painful Grade 2 Evidence mucosal internal bleeding and/or platelet refractory ANC &lt; 1000 cells/mm3 Hemoglobin &lt; 8.0 g/dL AST ( SGOT ALT ) &gt; 2 x ULN Intolerance bortezomib CC5013 past significant allergy either compound , boron mannitol Known hypersensitivity thalidomide development erythema nodosum Active infection serious comorbid medical condition Pregnant breastfeeding woman Prior malignancy last three year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , insitu prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>bortezomib</keyword>
	<keyword>Revlimid</keyword>
	<keyword>CC-5013</keyword>
</DOC>